P6.10: PROPIONYL-L-CARNITINE FOR INTERMITTENT CLAUDICATION. A COCHRANE REVIEW.

T. De Backer, V. Kamoen, R. Vander Stichele, L. Campens, D. De Bacquer, L. Van Bortel


To link to this article: https://doi.org/10.1016/j.artres.2014.09.161

Published online: 7 December 2019
The RI value was significantly reduced by beetroot ingestion (pre-beetroot RI = 0.75 ± 0.05 versus post-beetroot RI = 0.72 ± 0.05; pre-water RI = 0.75 ± 0.06 versus post-water RI = 0.76 ± 0.05; P = 0.02).

Conclusion: Our preliminary findings suggest that the supplementation of pharmacologic therapy with dietary nitrate through beetroot juice could prevent cardiovascular events and progression of renal disease in CKD patients.

P6.10 PROPIONYL-L-CARNITINE FOR INTERMITTENT CLAUDICATION: A COCHRANE REVIEW.
T. De Backer a,b, V. Kamoen b, R. Vander Stichele a, L. Campens b, T. van der Strom e, J. Van de Velde a, C. Giannattasio a,b, C. Fujiwara b, D. De Bacquer c, L. Van Bortela d

aUniversity of Manchester, Manchester, UK
bLeighton Hospital, Crewe, UK
cIntensive Care Unit 2, Ospedale Niguarda Ca’ Granda, Milano, Italy
dCardiologia IV, Ospedale Niguarda Ca’ Granda, Milano, Italy
edept of Epidemiology and Public Health, Ghent, Belgium
fCardiovascular Center, Ghent, Belgium

Intermittent claudication (IC) is a symptomatic form of peripheral arterial disease (PAD) (pain in the lower limbs with walking and relieved by rest). Propionyl-L-carnitine (PLC) is a drug which may lower the symptoms of PAD. Is PLC efficacious in improving clinical outcomes in IC patients?

For this Cochrane review randomized controlled trials in patients with IC receiving PLC compared with placebo or other intervention were selected. Pain-free and maximal walking performance were analyzed by standardized exercise test. ABI, quality of life and adverse events were assessed. 13 studies were included in this review (1423 patients). The results of these selected trials were brought together in patient pools. For the maximal walking distance, the mean difference in walking performance after use of PLC compared to placebo was an absolute increase of 50.86 m (95% CI 50.34 to 51.38) or a 26% relative improvement (23 to 28%). For the pain-free walking distance, the improvement in walking performance with PLC compared to placebo was an absolute increase of 32.98 m (32.60 to 33.37) or a 31% relative improvement (28 to 34%). PLC had an 0.09 (0.08 to 0.09) improvement in ABI over placebo. The adverse events of PLC were similar as in the control group and PLC seemed well tolerated and safe. PLC 1-2g a day costs 0.30 to 0.70 €.

PLC for IC shows a significant, though mild to moderate improvement of walking distances and ABI compared to placebo. The safety of PLC is comparable to placebo. In practice, PLC could be useful adjuvant to classic IC-therapies or when these are contra-indicated, not feasible or ineffective. This work is a Cochrane review. The data presented here presented are provisional (as the review has not yet been published).

The authors acknowledge the Cochrane Peripheral Vascular Diseases Group.

P6.11 PHOSPHODIESTERASE TYPE-5 INHIBITOR USE IN TYPE 2 DIABETES IS ASSOCIATED WITH A REDUCTION IN ALL CAUSE MORTALITY
S. Anderson a, D. Hutchings a, C. Kwok a, A. Trafford a, A. Heald a,b,

aUniversity of Manchester, Manchester, UK
bLeighton Hospital, Crewe, UK

Background: Phosphodiesterase type-5 inhibitors (PDE5is) exert cardioprotective effects in small mammal models of myocardial ischaemia. There is currently little data on whether a similar effect exists in humans. We determined whether PDE5i use in males with type 2 diabetes (T2DM) was associated with reduced mortality.

Methods: We retrospectively analysed the pseudoanonymised records of 48 GP practices in Cheshire, UK and identified all 7029 men (mean age 72.8 years) diagnosed with T2DM before 1 January 2007. Baseline clinical characteristics and PDE5i treatment data were obtained. Mean follow-up was 6.4 years (January 31, 2007) and all deaths were ascertained from GP records.

Findings: Of the 1,663 (23.7%) men prescribed a PDE5i, the proportion of deaths was significantly lower than those never prescribed (16.9% versus 29.4%). All-cause mortality rates (per 1000 person-years) were similarly lower (21.1 (1.9) to 24.54 (3.5). 23.5 to 36.5: P < 0.0001). There was a 38% reduction in all-cause mortality (univariate Cox proportional hazards HR: 0.62; (0.54-0.71); P < 0.0001) in men on a PDE5i over the period. This reduction remained but was attenuated (HR: 0.80 (0.65, 0.98); P < 0.05) after multivariate regression adjusting for age (1.11 (1.09–1.12); P < 0.0001 per year), smoking history (1.31 (1.16-1.47); P < 0.0001), HbA1c, systolic BP, creatinine levels, prescribed statins, aspirin and beta-blocker use.

Interpretation: Around 70% of deaths in T2DM are attributable to cardiovascular disease. Our data demonstrates that PDE5i use is associated with significantly reduced mortality in men with T2DM at high risk of CVD. Further evidence is required to elucidate the role of PDE5is in cardioprotection.

P7.1 ACUTE EFFECTS OF SMOKING OVER THE ENDOTHELIAL FUNCTION AND CENTRAL ARTERIAL HEMODYNAMICS IN YOUNG HEALTHY PEOPLE
T. Pereira a,b, J. Maldonado a,b, R. Brandão a,c, J. Conde a

aInstituto Politécnico de Coimbra, Coimbra, Portugal
bInstituto de Investigación e Formação Cardiovascular, Coimbra, Portugal

tIntroduction: The aim of this study was to assess the acute effects of smoking over the endothelial function and central arterial hemodynamics, in healthy and young smokers.

Methods: Thirty healthy young individuals, were allocated into two groups, matched for gender and age, according to their smoking habits: control group (CG; n = 15 non-smokers) and intervention group (IG; n = 15 smokers).

All the individuals were submitted to two clinical evaluations, basal and following 30 minutes (after smoking a cigar in the IG). Weight, height, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), flow-mediated dilation (FMD), aortic pulse wave velocity (PWV) and pulse wave analysis over the carotid artery (PWA) were assessed.

Results: CG and IG groups had similar baseline clinical and demographic characteristics, although the IG showed lower baseline FMD values (7.5 ± 2.8% versus 12.47 ± 4.63% in the CG; P < 0.001). The parallel pair-wise analysis confirmed significant variations in the IG, but not in the CG, with an increase in HR, brachial and central BP and PWV, and a significant decrease in FMD, revealing an important acute compromise of endothelium-dependent vasodilation after the cigar in the IG, with no changes in the CG.

Conclusion: Smoking has an acute and noteworthy pernicious effect over the vascular function in young and healthy individuals, compromising endothelium-dependent vasodilation, increasing heart rate, blood pressure and aortic stiffness.

P7.2 IDENTIFICATION OF VASCULAR AND CIRCULATING BIOMARKERS TO PREDICT OUTCOME IN PATIENTS AFFECTED BY SEPTIC SHOCK
P. Vallerio a,b, O. Belli b, F. Musca a, G. Monti c, L. Bonacchini a, M. Cazzaniga a, M. Stucchia, P. Meania, L. Frigerio a, M. Molteni a, F. Panzeri a, M. Alloni b, R. Fumagalli c, a, A. De Gasperi d, C. Giannattasio e,b

aMilano-Bicocca University, Milano, Italy
bCardiolog.CIV, Ospedale Niguarda Ca’ Granda, Milano, Italy
cIntensive Care Unit 2, Ospedale Niguarda Ca’ Granda, Milano, Italy
dIntensive Care Unit 3, Ospedale Niguarda Ca’ Granda, Milano, Italy

Introduction: Cardiovascular dysfunction is a well-recognized early complication of septic shock (SS). A hallmark of SS is a change in microvascular function and endothelial cell (EC) activation, contributing to multiple organ failure. Angiopoietin (Ang1-2) pathway has been reported associated with severity of illness and mortality. Aim: to evaluate prognostic and clinical role of functional vascular assessment in patients with SS.

Methods: We enrolled 20 patients from intensive care units with a diagnosis of SS. Clinical, hemodynamic, instrumental evaluations and blood sample collection were obtained at hospitalization (T1), and one week later (T2). We assessed echocardiographic left ventricular systolic function (LVF) and functional arteries evaluation with carotid-femoral PWV (Complor).

Results: During the follow-up 11 patients survived (S) and 9 died (D). S and D had similar ages (62 ± 8 vs 66 ± 11 yrs, means ± SD). MAP (80 ± 12 vs 81 ± 12 mmHg, means ±SD) and SOFA score (13 ± 4 vs 15 ± 4, means ±SD). At T1, D had a significantly higher cf-PWV than S (12.2 ± 3.9 vs 2 ± m/s, means ± SD; P < 0.05). Further more, considering all patients together, we found an inverse correlation between PWV and LVEF (p < 0.01). Finally, S had a significant T1-T2 increase in Ang1 (7393 ± 4857-7010 ± 47384 [10658-33645] [medians [25-75th]] p < 0.05) and a decrease in Ang2 levels (27783 ± 17625 vs 9008 ± 3565 means ± SD; p < 0.01). D patients showed an inverse trend.

Conclusions: In SS endothelial dysfunction caused by EC-activation is expressed by an increase of PWV, which was significantly different depending on outcome of patients. PWV also has a correlation with LVEF. The values of PWV could express an alteration of ventricular-vascular coupling, useful